Drugs / Recombinant Interleukin-7
Recombinant Interleukin-7
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00062049 | Apr 2003 → May 2011 | cancer of unknown primary site | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03941769 | Sep 2020 → Mar 2023 | acute myeloid leukemia, chronic myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Interleukin-7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03941769 ↗ |
| Known as | CYT107 | “To determine the safety and establish the optimal biologic dose of glycosylated recombinant human interleukin-7 (CYT107).” NCT03941769 ↗ |
| Known as | IL-7 | “Interleukin-7 (IL-7) has critical and nonredundant roles in T-cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine.” PMID 20068111 ↗ Jan 2010 |
| Known as | Interleukin-7 | “Interleukin-7 (IL-7) has critical and nonredundant roles in T-cell development, hematopoiesis, and postdevelopmental immune functions as a prototypic homeostatic cytokine.” PMID 20068111 ↗ Jan 2010 |
| Known as | recombinant human IL-7 | “We report here on the toxicity and biological activity of recombinant human IL-7 (rhIL-7) in humans.” PMID 20068111 ↗ Jan 2010 |
| Known as | rhIL-7 | “We report here on the toxicity and biological activity of recombinant human IL-7 (rhIL-7) in humans.” PMID 20068111 ↗ Jan 2010 |
| Modality | Protein / enzyme biologic | “We report here on the toxicity and biological activity of recombinant human IL-7 (rhIL-7) in humans.” PMID 20068111 ↗ Jan 2010 |
| Route | Subcutaneous | “Patients receive interleukin-7 (IL-7) subcutaneously on days 0, 2, 4, 6, 8, 10, 12, and 14 (for a total of 8 doses)” NCT00062049 ↗ |